gpt-dict.com

Phellinus linteus for Liver Health

Verdict: Insufficient Evidence

Across 4 PubMed studies, the evidence for Phellinus linteus in Liver Health grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
73%
Broadly consistent
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.44
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Styrylpyrones from Phellinus linteus Mycelia Alleviate Non-Alcoholic Fatty Liver in HFHF Diet-Fed Mice
PMID: 35624762 2022 Animal Study n = 9
Finding: Dose-dependent reduction of hepatic lipid and body weight; upregulated pgc-1a/sirt1/adiponectin, downregulated gck/srebp-1c (p<0.001)
Government
View on PubMed
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma
PMID: 38240856 2024 Animal Study n = 12
Finding: PL exerted dose-dependent antitumor effect in vivo; modulated tumor-immune microenvironment via FAK (p<0.01)
View on PubMed
Inhibitory Effect of Styrylpyrone Extract of Phellinus linteus on Hepatic Steatosis in HepG2 Cells
PMID: 36835095 2023 In vitro
Finding: 27% inhibition of lipid accumulation at 500 ug/mL; SOD +73%, GPx +67%; activated SIRT1/AMPK/PGC1-a
🟠 Limited quality
View on PubMed
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions: Study protocol for a randomized, double-blinded, placebo-controlled pilot trial
PMID: 32011496 2020 RCT (double-blind)
Finding: Protocol only, no results reported; primary endpoints are immune markers, not hepatic outcomes
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
MESIMA - phellinus linteus mycelium capsule; Marketing Category: unapproved drug other; NDC: 53144-1001; Labeler: Yein Trading & Global Co., Ltd; Manufacturer: Han Kook Sin Yak Pharmaceutical Co., Ltd.; Marketing Start Date: 2012-12-29 source↗
L4d TW TFDA / 衛福部
Neutral
桑黃（Phellinus linteus）之菌絲體及以椴木栽培之子實體，得作為食品原料使用；惟不得宣稱具有療效（如抗癌、治療腫瘤等），違者依《食品安全衛生管理法》及《健康食品管理法》規定處辦。 source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-phellinus-linteus-001 繁體中文版 →